Clinical Trial Update: Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of pembrolizumab with carboplatin and paclitaxel in triple-negative breast cancer is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• KEYTRUDA (PEMBROLIZUMAB)
• Taxol (paclitaxel)

Snippet

Sponsor: Tel Aviv Medical Center | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING